Editorial Comment to Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.

Arnout R Alberts, Ivo G Schoots, Monique J Roobol, Prostate-specific antigen-based prostate cancer screening: Past and future. International Journal of Urology. ,vol. 22, pp. 524- 532 ,(2015) , 10.1111/IJU.12750

Gwenaelle Gravis, Karim Fizazi, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre, Fréderic Rolland, Christine Théodore, Gael Deplanque, Jean Marc Ferrero, Damien Pouessel, Loïc Mourey, Philippe Beuzeboc, Sylvie Zanetta, Muriel Habibian, Jean François Berdah, Jerome Dauba, Marjorie Baciuchka, Christian Platini, Claude Linassier, Jean Luc Labourey, Jean Pascal Machiels, Claude El Kouri, Alain Ravaud, Etienne Suc, Jean Christophe Eymard, Ali Hasbini, Guilhem Bousquet, Michel Soulie, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 14, pp. 149- 158 ,(2013) , 10.1016/S1470-2045(12)70560-0

Christopher J. Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F. Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel Shevrin, Maha Hussain, Jorge A. Garcia, Robert S. DiPaola, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer The New England Journal of Medicine. ,vol. 373, pp. 737- 746 ,(2015) , 10.1056/NEJMOA1503747

Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair WS Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard, Johann De Bono, William Cross, Rob J Jones, George Thalmann, Claire Amos, David Matheson, Robin Millman, Mymoona Alzouebi, Sharon Beesley, Alison J Birtle, Susannah Brock, Richard Cathomas, Prabir Chakraborti, Simon Chowdhury, Audrey Cook, Tony Elliott, Joanna Gale, Stephanie Gibbs, John D Graham, John Hetherington, Robert Hughes, Robert Laing, Fiona McKinna, Duncan B McLaren, Joe M O'Sullivan, Omi Parikh, Clive Peedell, Andrew Protheroe, Angus J Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh KB Parmar, None, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial The Lancet. ,vol. 387, pp. 1163- 1177 ,(2016) , 10.1016/S0140-6736(15)01037-5

Alfredo Rodríguez-Antolín, Antoni Vilaseca, Sigrid V Carlsson, Karim A Touijer, Javier Romero-Otero, Borja García-Gómez, José M Duarte-Ojeda, Active surveillance for prostate cancer. International Journal of Urology. ,vol. 23, pp. 211- 218 ,(2016) , 10.1111/IJU.13016

Masaki Shiota, Masatoshi Eto, Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer International Journal of Urology. ,vol. 23, pp. 360- 369 ,(2016) , 10.1111/IJU.13091